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Fibrosis can be deﬁned as an excessive accumulation of extracellular matrix (ECM) components, ultimately
leading to stiffness, scarring and devitalized tissue. MicroRNAs (miRNAs) are short, 19–25 nucleotides (nt),
non-coding RNAs involved in the post-transcriptional regulation of gene expression. Recently, miRNAs have
also emerged as powerful regulators of ﬁbrotic processes and have been termed “ﬁbromiRs”. Oxidative
stress represents a self-perpetuating mechanism in ﬁbrogenesis. MiRNAs can also inﬂuence the expression
of genes responsible for the generation of reactive oxygen species (ROS) and antioxidant defence and are
termed “redoximiRs”. Here, we review the current knowledge of mechanisms by which “redoximiRs”
regulate ﬁbrogenesis. This new set of miRNAs may be called “redoxiﬁbromiRs”.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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Fibrosis is the ﬁnal common pathological feature of most
chronic inﬂammatory diseases. In some diseases, such as idio-
pathic pulmonary ﬁbrosis (IPF), liver cirrhosis, cardiovascular ﬁ-
brosis, systemic sclerosis and nephrosclerosis, extensive tissue
remodeling and ﬁbrosis can ultimately lead to permanent scarring
organ failure and death [1]. Fibrosis results when a normalB.V. This is an open access article u
Fernández),wound-healing response persists or becomes dysregulated,
usually in response to a severe or repetitive injury [2]. Regardless
of their distinct etiology and clinical features, chronic ﬁbrotic
disorders share the portfolio of growth factors, proteolytic en-
zymes, angiogenic factors and ﬁbrogenic cytokines that stimulate
the excessive production, deposition and contraction of ECM
components, such as hyaluronic acid, ﬁbronectin (FN), proteogly-
cans and interstitial collagens that progressively remodel and da-
mage the normal tissue architecture [3]. Transforming growth
factor-β (TGF-β) is considered to be the most potent and ubiqui-
tous pro-ﬁbrogenic cytokine [4,5]. TGF-β and local mechanical
forces, produced by inﬁltrated macrophages or resident cells,nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the activation of alpha-smooth muscle actin (α-SMA)-expressing
and ECM-producing myoﬁbroblasts, which are the key mediators
of ﬁbrotic tissue remodeling and ECM assembly [6,7]. The persis-
tent activation of myoﬁbroblasts leads to an excessive accumula-
tion of ECM components that progressively distorts normal tissue
architecture [2]. The origin of myoﬁbroblasts has been a con-
troversial subject in recent years because they differentiate from
various precursor cells that differ according to the nature of the
insult and the affected organ [8]. Thus, although activation of local
tissue ﬁbroblasts is thought to be the primary instigator of ECM
production following injury in many organs [8,9], epithelial and
endothelial cells [10–13], hepatic stellate cells [14,15], pericytes
[16], smooth muscle cells [17,18] and bone marrow-derived cells
[19–21] have been shown to differentiate into pro-ﬁbrotic myoﬁ-
broblasts during ﬁbrosis development. Whilst myoﬁbroblasts are
the primary drivers of ﬁbrosis, it is becoming increasingly clear
that various monocyte-derived cell populations can control the
ﬁbrotic process by exerting direct effects on matrix remodeling
and regulating activated myoﬁbroblasts [22].
Although it is well established that TGF-β and myoﬁbroblasts
play central roles in the development of ﬁbrosis, no effective
therapy is yet available to revert the evolution of this group of
severe connective tissue disorders.2. Oxidative stress and ﬁbrosis
Oxidative stress as a concept in redox biology and medicine
was formally deﬁned in 1985 by Helmut Sies [23] and it is cur-
rently known as an unbalance between the generation of ROS or
reactive nitrogen species (RNS) and the capacity of cells and tis-
sues to detoxify or scavenge them [24]. Mitochondria electron-
transport chain (ETC), membrane-bound NADPH oxidases (NOXs)
and endoplasmic reticulum (ER) are the three major intracellular
sources of ROS [25]. ROS-derived NOXs are particularly interesting
in ﬁbrogenesis, as described in the following sections. Glutathione
(GSH) is considered the most abundant molecule among en-
dogenous anti-oxidants [26]. GSH contributes to detoxify deleter-
ious metabolites maintaining redox homeostasis by preserving
redox potential and facilitating redox signaling [26]. The nuclear
factor-erythroid 2 related factor 2 (Nrf2) pathway is the major
regulator of cyto-protective responses to oxidative stress by reg-
ulating the expression of several enzymes involved in the anti-
oxidant response such as NOX:quinoneoxidoreductase1 (NQO1),
glutathione S-transferase (GSTs), cysteine–glutamate exchange
transporter and multidrug resistance associated protein [27,28].
ROS, generally through the action of its quintessential signaling
arm, hydrogen peroxide (H2O2), have a role in various signaling
cascades, such as in the response to growth factor stimulation and
control of inﬂammatory responses [29]. They participate in the
regulation of many cellular processes, including differentiation,
proliferation, growth, apoptosis, cytoskeletal regulation, migration,
and contraction [30]. ROS have crucial roles in critical physiolo-
gical processes [31], including the intracellular killing of bacteria
by neutrophil granulocytes [29], detoxiﬁcation by the liver [32],
thyroid hormone production [33] and crosslinking of ECM [34].
Despite its important role in physiological signaling, excessive
amounts of ROS cause direct cellular injury by inducing lipid and
protein peroxidation and damaging nucleic acids [35–37]. ROS
contribute to a wide range of pathologies including cancer, cardi-
ovascular diseases, neurological disorders, chronic inﬂammation
and autoimmune diseases [33]. Although many of the important
pathogenetic mechanisms that promote ﬁbrosis have been iden-
tiﬁed in the last decades, the precise molecular mechanisms in-
volved are not fully understood. There is a substantial and growingbody of evidences indicating the involvement of oxidative stress in
the development of ﬁbrosis in multiple organs.
2.1. Oxidative stress in pulmonary ﬁbrosis
Pulmonary ﬁbrosis is a lung disease that includes a hetero-
geneous group of lung disorders characterized by the progressive
and irreversible destruction of lung architecture caused by scar
formation that ultimately leads to death from respiratory failure
[1]. Among the ﬁbrotic lung diseases, IPF, with unknown etiology,
is the more common and severe form. Lung ﬁbrosis can also
develop after viral infections and after exposure to radiotherapy,
chemotherapeutic drugs and environmental toxins [38–41].
There are some evidences showing that ROS play an important
role in the development of pulmonary ﬁbrotic diseases. Oxidized
proteins and lipid products have been identiﬁed in exhaled air,
bronchoalveolar lavage ﬂuid and lung tissues from patients with
ﬁbrotic lung diseases. Importantly, increased ROS and oxidative
stress markers are detected in patients with IPF [42,43] and levels
of ROS negatively correlate with pulmonary function in IPF and
may predict disease severity [44]. An increase in oxidative DNA
damage has been also detected in patients with silicosis and as-
bestosis [45]. The mouse model of bleomycin-induced pulmonary
ﬁbrosis, the most commonly used experimental model, is asso-
ciated with a marked increase in ROS levels and in oxidized
proteins, DNA and lipids [46]. In this experimental model the
treatment with anti-oxidants attenuates ﬁbrosis [47–49], sug-
gesting a possible key role of oxidative stress in the development
of this pathology. TGF-β isoforms are secreted in an inactive, la-
tent form bound to a latency association protein (LAP). It has
been proposed that ROS can increase the TGF-β-induced ﬁbrosis
by activating latent TGF-β in asbestos-induced ﬁbrosis [50] and
by increasing the gene expression and secretion of TGF-β in many
cell types including alveolar epithelial cells (AECs) and macro-
phages [51]. ROS can also trigger the TGF-β1-induced ephitelial-
to-mesenchymal transition (EMT), a process that results in a loss
of epithelial markers and an acquisition of a mesenchymal phe-
notype in many ﬁbrotic diseases, including IPF [52–54]. During
EMT, epithelial cells lose their cell to cell junctions and the apical-
basal polarity. EMT also enables cells to acquire invasive prop-
erties, thus degrading ECM and synthesizing new ECM compo-
nents [55]. Several recent studies indicate that ROS production by
NOXs plays a central role in the pathogenesis of pulmonary ﬁ-
brosis and inﬂammation [47,56–59]. A recent study has found
that TGF-β1 regulated the expression of NOX4, one of the major
cellular ROS sources, thus generating oxidative stress [59]. Im-
portantly, these NOX4-produced ROS are required for TGF-β1-
induced myoﬁbroblast differentiation, ECM production and con-
tractility and genetic knock-down or pharmacologic inhibition of
NOX4 prevented bleomycin-induced lung ﬁbrosis in mice [59].
Moreover, NOX4 is up-regulated in lungs of mice treated with
bleomycin and in patients with IPF [59], further highlighting the
active role of ROS in the establishment and progression of pul-
monary ﬁbrosis. NOX4 is strongly expressed in the hyperplastic
alveolar epithelium of patients with IPF, particularly in type
2 AECs. Death of AECs in pulmonary ﬁbrosis is thought to be
mediated, at least in part, by TGF-β1 and it constitutes a key
initiating and perpetuating event in pulmonary ﬁbrosis [60,61].
Studies in a NOX4 knock-down mouse support that NOX4-de-
pendent ROS are critical for the induction of AECs death by
apoptosis and the subsequent development of lung ﬁbrosis, thus
conﬁrming an important role of NOX4 induction in the patho-
genesis of tissue ﬁbrosis [60].
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Renal ﬁbrosis, characterized by glomerulosclerosis and tubu-
lointerstitial ﬁbrosis, is the ﬁnal common manifestation of a wide
variety of chronic kidney diseases (CKD) [62]. The excessive and
progressive accumulation of ECM in the kidney promotes a gradual
destruction of renal tubules and functional nephrons. Oxidative
stress plays a central role in the pathogenesis of diverse chronic
inﬂammatory disorders including CKD. Patients with CKD have
markedly increased levels of oxidative stress, including increases
in lipid peroxidation, oxidation proteins products and changes in
GSH content [63–66]. The increased oxidative stress and in-
ﬂammation likely contribute to the high rates of morbidity and
mortality in this patient population [67]. Angiotensin II (Ang II),
the key contributor to the progression of renal diseases by acti-
vating pro-inﬂammatory and matrix synthesis pathways, induces
the generation of ROS by NOXs [68]. Other studies have shown a
close relationship between ROS production by NOXs and the de-
velopment of renal ﬁbrosis. For example, the production of FN in
mesangial cells induced by Ang II involves the reaction of NOX4-
derived superoxide ( ·−O2 ) with endothelial nitric oxidase synthase
(eNOS)-derived nitric oxide (NO) resulting in ONOO production
and uncoupling of eNOS, further promoting ·−O2 generation [69].
During hyperglycemia, NOX4 promotes podocyte apoptosis, an
event that signiﬁcantly contributes to the development of CKD
[70]. Although the origin of myoﬁbroblasts in the particular case of
the kidney is strongly debated [71], the role of oxidative stress has
been reported as a contributing factor in every cell type [72–79]. In
the context of renal disease, inhibition of NOX4 expression in
kidney ﬁbroblasts signiﬁcantly reduces α-SMA and ECM produc-
tion [73,80], thus conﬁrming the role of the NOX4-mediated redox
unbalance in the pro-ﬁbrotic transformation of renal ﬁbroblasts.
2.3. Oxidative stress in liver ﬁbrosis
Liver ﬁbrosis results from chronic damage to the liver in con-
junction with the accumulation of ECM proteins, which is a char-
acteristic of most types of chronic liver diseases [81]. The main
causes of liver ﬁbrosis in industrialized countries include chronic
hepatitis C virus (HCV) infection, alcohol abuse, and nonalcoholic
steatohepatitis (NASH). Advanced liver ﬁbrosis results in cirrhosis,
liver failure, and portal hypertension and often requires liver
transplantation [14]. Most of the chronic liver diseases, regardless
of the cause of the liver disorder, are characterized by increased
oxidative stress which induces liver injury and loss of liver func-
tion [82]. Oxidative stress has been also identiﬁed as a feature of
experimental models of ﬁbrosis and cirrhosis, bile duct ligation
(BDL) or carbon tetrachloride (CCl4) intoxication, suggesting their
possible role in liver ﬁbrosis. ROS contributes to the hepatic ﬁ-
brosis from various kinds of liver injuries, including alcohol abuse,
HCV infection, iron overload, and chronic cholestasis [83,84]. ROS
can stimulate the production of collagen, type I, alpha 1 (Col1α1)
and may act as intracellular signaling mediators of the ﬁbrogenic
action of TGF-β [85–87] in hepatic stellate cells (HSCs). Accumu-
lating evidence indicates that NOXs-mediated ROS play a critical
role in HSCs activation, a key event in the initiation and progres-
sion of liver ﬁbrogenesis due to the role of these cells in orches-
trating the ECM deposition in normal and ﬁbrotic liver. Direct
evidence for the contribution of NOX1 and NOX2 to hepatic ﬁ-
brogenesis was provided by attenuation of hepatic ﬁbrosis in ei-
ther NOX1 or NOX2-deﬁcient mice after CCl4 treatment or BDL
[88–90]. Several studies have shown that NOX4-generated ROS
participate in hepatic ﬁbrogenesis by inducing TGF-β1-mediated
HSCs activation [91] and triggering TGF-β- or death ligand-in-
duced hepatocyte apoptosis [91–93].2.4. Oxidative stress in cardiac ﬁbrosis
Cardiac ﬁbrosis is one of the detrimental factors that contributes
to heart failure (HF) during increased cardiac workload under con-
ditions such as hypertension or aortic stenosis. Increased accumula-
tion of ECM within the myocardium, especially in the interstitium
and in perivascular areas has been implicated in the progression of HF
[2,12,94–96]. A large body of work indicates that ROS generated by
NOXs and their interactions with NO are especially important in re-
dox signaling during the development of HF [97–99]. Interstitial ﬁ-
brosis induced either by Ang II infusion or chronic activation of the
renin-angiotensin system was abrogated in NOX2 knock-out mice
[100–102]. It has been also shown that NOX2-derived ROS contribute
to contractile dysfunction, myocardial atrophy, increased cardiomyo-
cyte apoptosis, interstitial ﬁbrosis, and inﬂammatory cell inﬁltration
in an in vivomodel of doxorubicin cardiotoxicity in mice [103], further
conﬁrming the possible role of NOX2 in cardiac ﬁbrogenesis. Some in
vitro studies have suggested that NOX4 is involved in the proliferation
of cultured human cardiac ﬁbroblasts and their transformation into
myoﬁbroblasts in response to TGF-β1 [104]. However, the relevance
of these results remains to be established in vivo.
2.5. Oxidative stress in skin ﬁbrosis
In dermatology, ﬁbrosis is the hallmark component of many skin
diseases, including systemic sclerosis (SSc), keloids, hypertrophic
scars, and graft-versus-host disease [105]. Fibrosis develops in the
dermis, the connective tissue layer between the basement mem-
brane and the epidermis and is mainly composed by ECM [106].
Fibrotic skin disorders can greatly impact patient quality of life with
organ dysfunction and psychological sequelae [107–109]. Oxidative
stress is thought to play a signiﬁcant role in cellular functions in-
volved in skin ﬁbrosis [110]. NOX-derived ROS are involved at var-
ious levels of skin ﬁbrosis and interfere with redox-sensitive in-
tracellular signaling pathways, including inhibition of protein tyr-
osine phosphatases, activation of certain transcription factors, and
modulation of enzymes [111]. In the skin, NOX enzymes play a key
role in excess ECM protein synthesis via indirectly activating key
protein tyrosine kinases [112] and may interfere with ECM de-
gradation by activating matrix metalloproteinases (MMPs) [113]. In
scleroderma, a complex connective tissue disorder characterized by
the excessive deposition of ECM proteins in the skin and internal
organs [114], the source of oxidative stress is attributed to ROS
production by ﬁbroblasts and activated leukocytes via NOX en-
zymes [115]. NOXs promote ﬁbroblast proliferation and differ-
entiation into myoﬁbroblasts by increasing α-SMA and collagen
(Col) expression and induce the expression of TGF-β1, the chemo-
kine ligand (CCL)-2 and PDGFR [115–121], thus highlighting the
importance of NOX enzymes in SSc.3. Redox-sensitive microRNAs
MiRNAs comprise a large family of conserved, small, non-coding
RNAs of 19–25 nucleotides (nt) long that regulate gene expression at
the post-transcriptional level by binding to the 3′-untranslated re-
gion (3′-UTR), coding sequences or 5′-untranslated region (5′-UTR) of
target messenger RNAs and leading to the inhibition of translation or
mRNA degradation [122,123]. Their discovery in 1993 by the la-
boratories of Ambros and Ruvkun, revolutionized the comprehension
of the post-transcriptional regulation of gene expression [124]. In
humans, miRNAs are predicted to control the activity of 30% of the
genome. At present there are more than 2500 miRNAs described.
Each miRNAs is transcribed by RNA polymerase II as a long precursor
RNA, called primary miRNA (pri-miRNA), which is then subjected to
nuclear processing by the Drosha–DGCR8’microprocessor’ complex.
Fig. 1. miRNAs regulating NOX4-mediated ROS production. TGF-β-mediated induction
of NOX4 contributes to ROS generation and transformation on ﬁbroblasts into myoﬁ-
broblasts. miRNAs inhibiting NOX4 expression abrogate this pro-ﬁbrotic transformation.
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miRNA) of 70 nt in length, is exported to the cytoplasm and then
further shortened by Dicer, yielding a 22-nt mature miRNA. In the
cytoplasm, miRNAs associate with speciﬁc mRNAs within a multi-
protein complex of Argonaute proteins, known as the RNA-induced
silencing complex (RISC), providing sequence-speciﬁc silencing ac-
tivity [124]. Considering hundreds of miRNA genes, each with many
dozens of targets, it is expected that regulation by miRNAs may occur
in any cellular function in health or disease [124–127]. In the last
years, it has been found that miRNAs are able to “ﬁne-tune” the
regulation of redox signaling, by direct interaction with Nrf2, as
mentioned above, the major transcriptional regulator of the defence
against ROS [27,28]. MiRNAs may also interact with its co-regulators
Kelch-like ECH-associated protein 1 (Keap1) and CNC homolog 1
(Bach1) or regulate the generation of ROS. These new subset of
miRNAs that either regulate redox pathways or are themselves
regulated by the cellular redox state have been termed “redoximiRs”
[128].4. RedoximiRs regulate ﬁbrogenesis by diverse mechanisms
In the last decade, miRNAs have been shown to be regulators of
pro- and anti-ﬁbrotic processes in human diseases and this subset
of miRNAs are called “ﬁbromiRs” [129]. Aberrant expression of
“ﬁbromiRs” drives initiation and progression of the ﬁbrotic process
in response to persistent tissue injury [129]. Moreover, TGF-β
signaling through Smad proteins can regulate the transcription of
miRNAs by DNA binding or the miRNA maturation by associating
with the Drosha/DGCR8 complex [130], suggesting a possible link
between miRNAs and ﬁbrogenesis. Given the important role of
oxidative stress in organ ﬁbrosis, and the fact that miRNAs are
implicated in ﬁbrogenesis, the potential intersection between the
sets of “redoximiRs” and “ﬁbromiRs” team has gained increasing
interest. We propose that this subset of miRNAs may be termed
“redoxiﬁbromiRs” and in the following sections we provide ex-
amples of representative members as well as describe their redox-
based mechanism of action and involvement in ﬁbrogenesis.
4.1. Regulation of ROS production and TGF-β–dependent myoﬁbro-
blast transformation
The best known example is constituted by those miRNAsregulating NOX4 expression. MiR-23b, miR-25 and miR-146a
down-regulate the expression of NOX4 [131–133] and as men-
tioned earlier NOX4–dependent generation of H2O2 was required
for TGF-β–induced myoﬁbroblast differentiation, ECM production
and contractility [59] (Fig. 1). Importantly, He et al. demonstrated
that miR-146a inhibited the pro-ﬁbrotic TGF-β pathway by tar-
geting SMAD4 and also reduced HSCs proliferation and induced
HSCs apoptosis [134]. Other study showed that miR-146a modu-
lated the TGF-β–induced transformation of human dermal ﬁbro-
blasts also by targeting SMAD4 [135], suggesting an anti-ﬁbrotic
role of miR-146a not only in liver but also in skin. Results from Fu
et al. indicated that miR-25 contributed to the regulation of NOX4
expression in diabetic nephropathy (DN) [131], one of the major
microvascular complications of diabetes and the most common
cause of end-stage renal disease [136]. Thus, miRNAs can reduce
ROS production by inhibiting NOX4 expression and modulating
the levels of these miRNAs may represent a therapeutic strategy
for the treatment of incurable diseases such as organ ﬁbrosis.
4.2. Regulation of anti-oxidant responses and EMT process
Regarding the miRNAs regulating cellular anti-oxidant defenses
[137], those monitoring the Nrf2 signaling pathway are some of
the most studied. Nrf2 signaling appears to be important for the
pathogenesis of ﬁbrosis. Several studies have demonstrated that
Nrf2-deﬁcient mice are more susceptible to chemically induced
oxidative stress than wild-type mice, particularly in the liver
[45,138].
MiR-34a has been shown to become up-regulated in the ageing
liver acting as a post-transcriptional repressor for key genes re-
lated to oxidative defense in the rat liver during the ageing process
[139]. The target genes repressed by miR-34a do not only include
two key genes, Sirtuin 1 (Sirt1) and microsomal glutathione
S-transferase 1 (Mgst1), which have an important role in cellular
redox balance and resistance to oxidative stress in the liver
[140,141], but also their transcriptional activator factors, Sp1 and
Nrf2 [139]. MiR-34a has been demonstrated to exert a pro-ﬁbrotic
role in a dimethylnitrosamine (DMN)-induced hepatic ﬁbrosis in
rats by targeting the acyl-CoA synthetase long-chain family
member 1 (ACSL1) [142], thus suggesting the implication of miR-
NAs in the regulation of lipid/fatty acid metabolism involved in the
development of liver ﬁbrogenesis. In mice with preexisting pa-
thological cardiac remodeling and dysfunction due to myocardial
infarction (MI) or pressure overload via transverse aortic con-
striction (TAC), administration of locked nucleic acid (LNA)-based
antimiRs induced a decrease in miR-34a expression, improved
systolic function and reduced cardiac ﬁbrosis [143], providing
evidence that silencing of the entire miR-34 family can protect the
heart against pathological cardiac remodeling and improve cardiac
function. Another study demonstrated that miR-34a is induced
after acute MI and, importantly, the inhibition of miR-34a en-
hanced cardiac contractile recovery after acute MI [144]. These
results strongly indicate that the inhibition of miR-34a is a po-
tential therapeutic strategy to improve cardiac contractile function
after acute myocardial infarction. In keeping with the growing
interest on the regulation of antioxidant defenses by miRNAs, our
group has recently described one miRNA, miR-433, which targets
GSH biosynthetic enzymes in an Nrf2-independent manner, re-
sulting in decreased GSH levels and antioxidant capacity with
important implications for endothelial function as well as for
kidney and liver ﬁbrosis [145].
Of notice, Yang et al. showed an increase in miR-27a and miR-
27b expression induced by c-Myc in mouse models of liver ﬁbrosis
relating it to a reduction in both the expression of GSH synthetic
enzymes and Nrf2 [146], both major constituents of the anti-oxi-
dant cellular pathways. It has been shown that the down-
Fig. 2. Different mechanisms of action of “redoximiRs” contribute to the regulation
of the EMT process. Several miRNAs, regulating antioxidant responses and/or being
regulated by ROS, can cooperate to control the expression of different genes related
to EMT, thus having an important role in the development of ﬁbrogenesis.
Fig. 3. miR-21 as an archetypal “redoxiﬁbromiR”. TGF-β1 and ROS induce the up-
regulation of miR-21. This pro-ﬁbrotic “redoximiR” regulates key signaling path-
ways with speciﬁc relevance in the context of organ ﬁbrosis.
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tivated rat HSCs induce a switch towards a more quiescent HSC
phenotype by restoring their ability to accumulate cytoplasmic
lipid droplets and decreasing HSCs proliferation [147]. The retinoid
X receptor alpha (RXRα) was conﬁrmed to be the target of both
miRNAs [147], highlighting the importance of regulating fatty acid
metabolism and cell proliferation during HSCs activation in an
attempt to counteract hepatic ﬁbrosis.
Members of the miR-200 family are not only the object of reg-
ulation by changes in the redox state [128] but are also are up-
regulated by oxidative stress themselves [148] (Fig. 2). Of interest,
one speciﬁc member of the miR-200 family, miR-200a, is down-
regulated in the TGF-β1-mediated activation of HSCs but during
liver ﬁbrosis progression in humans and mice it has been reported
to increase [149]. This is in line with the induction in the expression
of miR-200a in oxidative stress conditions in order to target Keap1,
which negatively modulates the stability of the master antioxidant
regulator Nrf2 [150] (Fig. 2). Noteworthy, miR-200 family members
have also been closely related to EMT (Fig. 2). This process has been
proposed to be an important mechanism responsible for the accu-
mulation of interstitial myoﬁbroblasts and Col production during
kidney ﬁbrosis [151], although this concept is currently still con-
troversial [152,153]. Targets of miR-200a also include pro-ﬁbrogenic
factors such as TGF-β2 and β-catenin, both EMT-related down-
stream genes [154], further conﬁrming the involvement of miR-
200a in the anti-oxidant response of HSCs during liver injury. Of
interest, ROS induce the expression of miR-200c, which in turnrepresses the Zinc ﬁnger E-box binding homeobox 1 (Zeb1). This
transcription factor is one of the master EMT-inducing genes asso-
ciated with the mesenchymal phenotype and negatively modulates
E-cadherin [155], whose down-regulation is a hallmark of EMT. FN
is another annotated target gene for miR-200c [156], thus high-
lighting the role of miR-200c in organ ﬁbrogenesis.
The Let-7 family of miRNAs has been implicated in the patho-
genesis of ﬁbrosis in several organs such as lung, skin or kidney
[157–160]. Let-7d is transcriptionally inhibited by TGF-β and is
signiﬁcantly decreased in the alveolar epithelium in lungs from
patients with IPF [159]. Let-7d target genes include high mobility
group A2 (HMGA2) [161] (Fig. 2), which is a key factor in the TGF-β-
EMT-induced process associated to activation of the zinc ﬁnger Snail
and the basic helix–loop–helix (bHLH) Twist transcription factors
and E-cadherin suppression [162]. Let-7a is down-regulated in skin
tissue and ﬁbroblasts from SSc patients and negatively regulates the
expression of Col [158]. Moreover, over-expression of let-7a im-
proved the skin ﬁbrosis induced by bleomycin in mice [158]. A
study comparing miRNA proﬁles of patients with SSc and healthy
control individuals identiﬁed Let-7g as involved in SSc pathogenesis
[157]. Finally, Let-7b expression was reduced in models of both
diabetic and non-diabetic renal ﬁbrosis. Over-expression of Let-7b
prevented the pro-ﬁbrotic effects of TGF-β by repressing type I TGF-
β receptor (TGFBR1) in rat proximal tubular epithelial cells [160]. Of
note, some Let-7 family members have been shown to decrease
Bach1 expression, a transcriptional repressor of Nrf2 [163] (Fig. 2),
in a human hepatoma cell line, thereby attenuating oxidative injury
via enhancement of Nrf2-mediated heme oxygenase-1 (HO-1) gene
expression [164]. Similarly, miR-155 has been reported to inhibit
Bach1 expression [128] (Fig. 2). Up-regulation of miR-155 correlated
with the degree of lung ﬁbrosis in mice and was also found to be
over-expressed in patients with IPF [159,165]. The expression of
miR-155 increased during TGF-β-induced EMT in mammary epi-
thelial cells through Smad4-mediated transcriptional up-regulation
and facilitated loss of cell polarity and tight junctions by targeting
the Ras homolog family member A (RhoA) [166], implicating miR-
155 in EMT (Fig. 2).
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MiR-21, one of the most extensively studied miRNAs, is also as-
sociated with oxidative stress [167]. Inhibition of miR-21 attenuated
ﬁbrosis in the heart, [168,169], kidney [170], lung [171] and skeletal
muscle [172], evoking miR-21 inhibitors as a potential anti-ﬁbrotic
therapy. It has been proposed that the transcription factor NF-κB
positively regulated miR-21 expression under H2O2-induced oxida-
tive stress in cardiomyocytes [167] and the up-regulation of this
miRNA has been suggested to lie downstream of NOX activation
[173]. Moreover, H2O2-induced ROS activity and cardiomyocyte
apoptosis were partly protected by overexpression of miR-21 and
displayed an important role in ROS-mediated cardiomyocyte injury
[167]. MiR-21 has been implicated in cardiac ﬁbrosis development as
the expression of this miRNAwas enhanced in the failing heart [169].
By targeting sprout homolog 1 (Spry1), an extracellular regulated
kinase (ERK) inhibitor, miR-21 induces an up-regulation of ERK sig-
naling. In vivo silencing of miR-21 was shown to reduce cardiac ERK-
mitogen-activated protein (MAP) kinase activity, to inhibit interstitial
ﬁbrosis and to attenuate cardiac dysfunction in a mouse pressure-
overload-induced disease model [169]. Results of another study
shown that miR-21 played an important role in TGF-β-induced en-
dothelial-to-mesenchymal transition (EndMT), a process that con-
tributes to ﬁbroblast formation in ﬁbrotic diseases of the heart
[12,174], kidney [175–177], lung [178], liver [13] and carcinoma-as-
sociated ﬁbrosis [179], by targeting the protein phosphatase and
tensin homologue (PTEN) thus regulating the AKT signaling pathway
[180]. Liu et al. [171] conﬁrmed the pro-ﬁbrotic activity of miR-21 in
human IPF and in a mouse model of bleomycin-induced lung ﬁ-
brosis. The expression of miR-21 is increased in experimental ﬁbrosis
and importantly in patients with IPF [171] and miR-21 up-regulation
was proportional to the severity of lung ﬁbrosis in the bleomycin
mouse model. The enhanced expression of miR-21 led to the sup-
pression of Smad7 expression and favoured the assembly of Smad2/
3-Smad4 heterodimers, a crucial event in the pro-ﬁbrogenic TGF-β
signaling pathway [173]. Administration of miR-21 antisense oligo-
nucleotides attenuated bleomycin induced-lung ﬁbrosis [171]. Mir-
21 has been reported to be increased in SSc skin tissues and ﬁbro-
blasts and the regulation of Smad7 expression was also described in
this context [181]. Studies on the role of miR-21 in renal ﬁbrosis
further conﬁrmed the interaction of this miRNA with the TGF-β
signaling [170]. TGF-β increased the expression of miR-21 in tubularFig. 4. Targets and anti-ﬁbrotic actions of miR-9-5p. TGF-β and ROS induce miR-9-5p e
self-limit its pro-ﬁbrogenic action. miR-9-5p inhibits the transformation of ﬁbroblasts in
different organs.epithelial cells. Smad3 knock-down mice were protected from miR-
21 up-regulation and ﬁbrosis after unilateral uretral obstruction
(UUO) kidney injury, a useful and widely used model to examine
mechanisms of tubulointerstitial ﬁbrosis in vivo [182], indicating that
the TGF-β-induced up-regulation of miR-21 is mediated by Smad3
[170]. In addition to the induction of miR-21 in the mouse ﬁbrotic
kidney, this miRNA was also found to be up-regulated in human ﬁ-
brotic kidney samples, especially in areas with abundant presence of
myoﬁbroblasts [183]. Importantly, serum levels of miR-21 were sig-
niﬁcantly elevated in patients with kidney ﬁbrosis, showing good
correlationwith the severity of ﬁbrogenesis [183], suggesting miR-21
as a potential biomarker of kidney ﬁbrosis. It has been proposed that
miR-21 is also involved in the development of skeletal muscle ﬁ-
brosis by targeting PTEN and SMAD7 [172]. Importantly, the same
authors described the increased expression of miR-21 in muscle
biopsies of Duchenne muscular dystrophy (DMD) patients, corre-
lating with extensive tissue ﬁbrosis [172], thus conﬁrming the role of
this miRNA in skeletal muscle disease. Targets and signaling path-
ways regulated by miR-21 are summarized in Fig. 3.
4.4. Regulation of ROS production and TGF-β signaling pathway
Recently, we have described a clear example of a novel “re-
doximiR” regulating organ ﬁbrogenesis. MiR-9-5p negatively reg-
ulates NOX4 expression, thus controlling ROS-NOX4 production, but
it is also up-regulated in the presence of H2O2. By inhibiting NOX4
and type II TGF-β receptor (TGFBR2) expression, miR-9-5p abrogated
the TGF-β-dependent pro-ﬁbrotic transformation of lung ﬁbroblasts,
mesothelial cells (MCs) [184] and dermal ﬁbroblasts (unpublished
data) into myoﬁbroblasts. Consistently, increased miR-9-5p levels
reduced the pro-ﬁbrogenic activities of TGF-β1 by inhibiting TGF-
β1-mediated signaling. Increased expression of miR-9-5p results in a
dramatic attenuation of bleomycin-induced lung [184] and skin ﬁ-
brosis (unpublished data). On the contrary, inhibition of miR-9-5p
both in vitro and in vivo resulted in a signiﬁcant reduction of its anti-
ﬁbrotic effect [184]. Importantly, in lung specimens from patients
with IPF and in omentum-derived MCs from patients subjected to
peritoneal dialysis (PD) high levels of miR-9-5p were encountered.
We propose that miR-9-5p may have a protective role in the in-
itiation and progression of human ﬁbrosis. It is conceivable that, for
homeostatic purposes, the crucial pro-ﬁbrogenic cytokine TGF-β
triggers counteracting responses that self-limit its deleterious action,xpression. TGF-β1 may induce the expression of regulators, including miR-9-5p, to
to myoﬁbroblasts by targeting TGBR2 and NOX4, thus counteracting ﬁbrogenesis in
Fig. 5. Overview of miRNAs implicated in the pathogenesis of ﬁbrosis. Selected “ﬁbromiRs” inducing (green arrows) or blocking (red blunt arrows) organ ﬁbrosis are shown.
Those being part of the “redoximiRs” set of miRNAs are represented in bold, thus generating a novel set of miRNAs called “redoxiﬁbromiRs”. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
M. Fierro-Fernández et al. / Redox Biology 7 (2016) 58–6764such as miR-9-5p (Fig. 4). In addition, miR-9-5p could also represent
a biological marker and a novel therapeutic target in lung ﬁbrosis,
still largely a devastating and incurable condition.5. In summary
It has been demonstrated that oxidative stress and the anti-
oxidant defences are crucial for ﬁbrosis development and perdur-
ability. The ﬁnding that miRNAs play an important role in the pa-
thogenesis of organ ﬁbrosis (Fig. 5) and even more, the recent
discovery of the existence of miRNAs regulating and being regulated
by ROS have uncovered the potential use of miRNAs as biomarkers
in the diagnosis, prognosis and response to treatment. The novel set
of miRNAs regulating ﬁbrogenesis through redox-based mechan-
isms may be termed “redoxiﬁbromiRs”. Therapeutic approaches
based on “redoxiﬁbromiRs” modulation may represent a novel al-
ternative for many challenging human diseases, including ﬁbrosis.Acknowledgments
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